The role of allogeneic hematopoietic SCT (allo-HCT) in multiple myeloma (MM) remains controversial. A total of 58 patients received an allo-HCT (25 of them with myeloablative conditioning-allo-MAC-and 33 with reduced-intensity conditioning-allo-RIC) at our institution over a 28-year period. The CR rate for allo-MAC was 36%. The incidence of grade III-IV acute GVHD (aGVHD) and chronic GVHD (cGVHD) was 28% and 39%, respectively The TRM at any time was 60% and the main causes of death were aGVHD or infectious complications not directly related to GVHD. The estimated PFS and OS at 15 years were 8% and 15%, respectively. The CR rate with allo-RIC was 45%. The incidence of grade III-IV aGVHD and cGVHD were 24% and 41%, respectively. The TRM at any time was 33% and was mainly related to aGVHD. The estimated PFS and OS at 5 years were 22% and 38%, respectively. Despite its high TRM, a proportion of patients with high-risk myeloma (early relapse and newly diagnosed ultrahigh risk) may obtain long-term disease control with allo-HCT. New approaches aimed at decreasing the incidence of aGVHD, and consequently to decrease the TRM, are needed.
INTRODUCTION
Since the introduction of melphalan and prednisone, the treatment of multiple myeloma (MM) has markedly improved. The major advances have been the introduction of high-dose therapy followed by autologous stem cell support (ASCT) and, more recently, the incorporation of novel antimyeloma drugs. However, MM remains an incurable disease with significant life expectancy shortening. 1 Allogeneic hematopoietic SCT (allo-HCT) is a therapeutic measure with curative potential. The advantages of allo-HCT over ASCT are the infusion of a nontumor contaminated graft and the potential graft-vs-myeloma effect. 2, 3 However, allo-HCT in MM has the two important shortcomings of a TRM rate of 30-50% and a high post-transplant relapse rate resulting in only about 15% of long-term survivors in molecular remission. 4, 5 Unfortunately, the use of peripheral blood progenitor cells and T-cell depletion have not improved the results of myeloablative allo-HCT. 6, 7 Allogeneic transplantation with reduced-intensity conditioning (allo-RIC) results in a lower TRM but also in a higher relapse rate. Despite a reported PFS of 25% beyond 7 years, 8 the role of allo-RIC remains controversial. 9 However, it must be considered that allo-RIC is often done in advanced stages of the disease, when the chances of success are particularly low, as most patients with high-risk myeloma (that is, those with early relapse or high-risk cytogenetics and advanced international staging system (ISS) score) 10, 11 still have a dismal prognosis even when treated with novel agents.
We report the results of allo-HCT at our institution over a period of 28 years outside clinical trials in patients with MM.
PATIENTS AND METHODS Patients
A total of 58 patients with MM received an allo-HCT at our institution from February 1986 to August 2012, 25 of them with myeloablative conditioning regimen (allo-MAC) and 33 with reduced-intensity conditioning (allo-RIC). All these procedures except two were done as routine clinical practice (that is, outside investigational clinical trials).
Disease response
Response to transplant was defined according to the International Myeloma Working Group criteria 12 with addition of the minimal response category. CR was defined as negative immunofixation in serum and urine and o5% plasma cells in the BM aspirate. Response was assessed at day +100 and at 6 months post transplantation.
Definitions
PFS was defined as the time from transplantation to the date of progression or death from any cause or last follow-up. OS was defined as the time from the date from transplantation to the date of death or last follow-up. TRM was defined as death due to any cause other than disease progression or relapse occurring at any time after transplantation. Deaths due to infection (bacterial, fungal or viral) in the context of active GVHD were considered to be related to GVHD.
Statistical analysis
OS and PFS were estimated by the Kaplan-Meier method 13 and curves were compared with the log-rank test.
14 Patient characteristics were compared using the Fisher exact test for categorical variables and the Mann-Whitney test for continous variables. All patients were updated for response state and survival as of 28 February 2014 . No patient was lost to follow-up. , conditioning regimens and GVHD  prophylaxis  From February 1986 to April 2009, 25 patients (19M/6F; median  age 43 years: range 23-53 years) received an allo-MAC from an HLA identical sibling donor. The stem cell source was BM in 9 patients and peripheral blood in 16 patients. Disease status at the time of transplant was first response in 11 patients (44%) (4 CR, 7 PR), sensitive relapse in 3 (12%) (1 CR, 2 in PR) and refractory disease in 11 (44%). The conditioning regimens were heterogeneous: 7 melphalan/TBI, 6 CY/TBI, 4 CY/melphalan/TBI, 3 BU/CY, 3 BCNU/melphalan/CY/TBI, 2 BU/melphalan). GVHD prophylaxis consisted of CY and MTX (11 patients), T-cell depletion (11 patients) and CY/prednisone (3 patients). The patient characteristics are shown in Tables 1 and 2 .
RESULTS

Patient characteristics
Between April 2001 and August 2012, 33 patients (19M/14F; median age 49 years: range 29-66 years) received an allo-RIC, 24 of them (73%) from an identical sibling donor and 9 (27%) from an unrelated donor (5 match unrelated-10/10-and 4 mismatched -9/10). The stem cell source was peripheral blood in all cases. All nonmyeloablative allo-RIC were done at relapse except in seven patients who did not achieve a CR after front-line ASCT and received an allo-RIC in a tandem transplant strategy. 15 Eighteen patients (55%) had sensitive relapse (first relapse 14 patients, second relapse 4 patients) and their response status was: CR (3), VGPR (2) and PR (13) . Eight patients (24%) had refractory disease at the time of allo-RIC. Conditioning regimens consisted of fludarabine (150 mg/m ) and TBI (2 Gy) (4 patients) and fludarabine, melphalan and peritransplant bortezomib in 2 patients included in a prospective trial. 16 GVHD prophylaxis consisted of CY and MTX (6 patients) or CY and mycophenolate (27 patients). All patients in the allo-RIC group had received a prior single ASCT. The patient characteristics are shown in Tables 1 and 2 .
GVHD
The incidence of acute GVHD (aGVHD) grade II-IV and III-IV in the allo-MAC group were 40% and 28%, respectively. In the allo-RIC group, the incidences of aGVHD grade II-IV and III-IV were 40% and 24%, respectively (Table 3) .
Eighteen patients of the allo-MAC group were evaluable for chronic GVHD (cGVHD). Seven patients (39%) developed cGVHD (five limited and two extensive). In the allo-RIC group, eleven (41%) of the 27 evaluable patients developed cGVHD (eight limited and three extensive). There were no significant differences in aGVHD or cGVHD according to the type of donor in the allo-RIC group. In the allo-MAC group, aGVHD resulted in a significant time-to-progression prolongation, whereas cGVHD had no significant impact on tumor control. Conversely, in allo-RIC aGVHD did not have impact on relapse rate, whereas cGVHD was associated with a significant time-to-progression prolongation.
Response status after transplantation
On an intention to treat basis, the response rate at 3 months after allo-MAC was 64% (CR 36, VGPR 8 and PR 20%), whereas 8% of the patients remained with refractory disease. A total of nine patients Abbreviations: allo-MAC = allogeneic myeloablative conditioning; allo-RIC = allogeneic reduced-intensity conditioning; F = female; M = male. died before day +100 and were considered as not evaluable for response except two of them who died on day +36 and +60, respectively, with a documented CR. Chemosensitive disease at the time of conditioning was associated with a better posttransplant response. Thus, among the 11 patients in first response who proceed to transplant, 5 achieved CR (one of them died on day +60), 1 VGPR and 3 PR, whereas 2 patients died before day +100 due to transplant-related toxicity and were not evaluable for response. Among the three patients who had sensitive relapse, two achieved CR and one VGPR. In contrast, among the 11 refractory patients only 2 achieved CR (one of them died on day +36) and 2 patients PR while 2 patients remained with refractory disease. Five patients died before day +100 because of infectious complications and were not evaluable for response. The overall response rate on an intention to treat basis at 3 months after allo-RIC was 57% (CR 27%, VGPR 12%, PR 18%) and 21% had refractory disease. The response rate improved over time and the CR rate increased from 27-45%. There was no significant correlation between the disease status at the time of conditioning and the post-transplant CR rate. In fact, in patients who were in first line before allo-RIC the CR rate was 43% as compared with the 44% in patients in sensitive relapse or 50% in patients with refractory disease.
TRM
In the allo-MAC group, nine patients (36%) died before day +100 from transplant-related toxicity, whereas the overall TRM at any time was 60%. The causes of death were infectious complications related to GVHD in six patients (24%), infections not related to GVHD in seven cases (28%) and veno-oclusive disease and multiorgan failure (one patient each).
In the allo-RIC group, seven patients (21%) died before day +100, whereas the overall TRM at any time was 33%. The causes of death were infections related to GVHD in nine patients, and pulmonary toxicity and post-transplant lymphoma (one patient each). The causes of TRM in both groups are depicted in Table 3 .
Relapse
The relapse rate after myeloablative allograft was 32%. There are two patients who remain in continued CR at 25 and 28 years beyond transplantation. Two additional patients are long-term survivors after extramedullary relapses. One patient who achieved a PR after transplant had extramedullary relapse 6 months after transplantation and achieved CR after DLI. This patient had a second extramedullary relapse 14 years later that was successfully treated with only radiation therapy achieving a second CR. A second patient who achieved also a PR after transplant had an extramedullary relapse (paravertebral mass at C6 level) at 32 months post transplant and achieved a CR after chemotherapy plus radiation therapy, which is maintained 13 years later.
The relapse rate after allo-RIC was 51%. Six patients remain alive in continued CR from 2-12 years of follow-up. One patient relapsed 4 months post transplant with soft-tissue plasmacytoma and achieved CR after radiation therapy alone, which is maintained after 8 years of follow-up. One additional patient relapsed 2 months post transplant with soft-tissue plasmacytoma, was given radiation therapy plus DLI and achieved CR, which is maintained 12 years later.
The cumulative incidence of TRM and relapse after allo-MAC and allo-RIC are shown in Figure 1 .
Survival After a median follow-up for alive patients of 18.1 years after allo-MAC transplantation, the estimated PFS and OS at 10 years was 8% and 15%, respectively, with a stable plateau beyond 7 years from transplantation. After a median follow-up for alive patients of 5.3 years after allo-RIC transplantation, the estimated PFS and OS at 5 years were 22 and 38% with a stable plateau with no progressions or deaths beyond 7 years from transplant. After a median follow-up for alive patients of 8.6 years for the overall series, there was a trend for a longer PFS (P = 0.22) and a significantly longer OS (P = 0.04) in favor of the allo-RIC group (Figures 2 and 3 ). There were no significant differences in PFS and OS between patients who received the allogeneic transplant after one line of therapy vs those who received more than one line in both MAC and RIC conditioning. Of interest, six of the eight patients with continued CR in whom flow cytometry has been done, all were MRD negative. The three patients with available FISH study had high-risk cytogenetics (del 17p, t(4;14) and t(14;16)).
DISCUSSION
Despite the introduction of ASCT and novel antimyeloma agents, MM still remains an incurable disease, the outcome being particularly poor for patients with high-risk factors at diagnosis and after relapse. Allo-HCT is a potentially curative procedure for MM even in patients with advanced disease. 4, 5, 9, 15, 17 Although allo-HCT with conventional MAC is associated with a high TRM, it is of interest that 10-25% of patients undergoing an allogeneic transplant are long-term disease free and likely cured. 4, 5, 9, 15 Garhton et al. 6 reported the EBMT experience showing a significant decrease in TRM over time (from 46% in the period 1983-1993 to 30% between 1994 and 1998). Unfortunately, in a more recent EBMT study, the TRM with allo-MAC for the period 1998-2002 was 37%. 18 Attempts to decrease the TRM using peripheral blood progenitor cells or T-cell depletion 19, 20 have not resulted in improved results. This led to the introduction of allo-RIC in an attempt to decrease the TRM while retaining the beneficial graft-vs-myeloma effect. Taking into account the importance of the achievement a low tumor mass at the time of transplantation for the success of the allo-RIC, this type of transplant has been usually performed either at sensitive relapse or as part of a tandem approach in the up-front therapy setting. 21, 22 It is of note that in the series with longest follow-up, including up-front and relapsed patients, the PFS is about 25% at 5 years and between 16 and 24% at 10 years and the OS about 55% at 5 years and from 30 to 40% at 10 years. 23, 24 It is important to consider that this high-risk procedure is usually only offered to patients with the poorest short-term predicted outcome with conventional therapies. As a matter of fact, the number of patients undergoing allo-HCT for MM in institutions with a high-transplant activity is low and the published results usually come from registry studies rather than single institution series.
Our results with allo-MAC are similar to those reported in previous studies. The incidence of aGVHD grade II-IV is 40% and the TRM of 36% and 60% at day +100 and at any time, respectively. The main causes of TRM in our series were associated with GVHD and infectious complications. Despite the fact that about half of our patients had refractory disease at the time of transplantation, it is of interest that there is a survival plateau beyond 10 years with two patients cured. The proportion of 8% (2/25) of patients undergoing an allo-MAC long-term disease free and likely cured is similar to the reported in the EBMT and Seattle experience. [4] [5] [6] 18 It is also of note that two additional patients were successfully treated for isolated extramedullary relapses achieving long-lasting CRs after the salvage therapy, with local radiation with or without DLI.
Our results with the allo-RIC are also close to those previously reported, with an early TRM of 21% and an overall TRM of 33%. At 5 years, the PFS is 22% and the OS 38%, showing a stable plateau with six patients alive in continued CR from 2 to 12 years beyond the allo-RIC procedure. As in the allo-MAC group, it is of interest that two patients, who had an early post-transplant extramedullary relapse, are long-term disease free after radiation therapy alone or radiation therapy plus DLI.
Bensinger et al. 24 reported the long-term outcome of the Seatle experience in allogeneic transplantation in MM. In this series, the nonrelapse mortality at 2 years was 55% and 18% with allo-MAC and allo-RIC, respectively. For patients undergoing myeloablative allograft, the PFS and OS at 15 years were 8% and 11%, respectively. For patients undergoing nonmyeloablative allografts, the PFS and OS at 10 years were 16% and 39%, respectively. As in the Seatle and the EBMT series, 19, 24 we found a higher cumulative TRM and a lower relapse rate in the allo-MAC group compared with the allo-RIC.
Concerning registry studies, Kumar et al. 25 analyzed the outcome of 1207 patients who underwent an allo-HCT over a period of 16 years reported to the Center for International Blood and Marrow Transplantation Research. The authors analyzed the outcome in three cohorts based on the year of transplantation. Neither the PFS (21% vs 22% vs 14%) nor the OS (30% vs 30% vs 29%) were significantly different among the three cohorts. Of interest, despite the limited number of patients, in our series the OS was significantly longer in the allo-RIC and there was a trend toward a better PFS in the allo-RIC group.
Given this high-morbimortality of the allogeneic transplant, the role of allogeneic transplant in MM has become a matter of controversy and it is stated that it should be only performed in the context of clinical trials. 20 However, there are two situations in clinical practice in which the expected survival of patients with MM is very limited even with the use of novel antimyeloma agents and in which allogeneic transplantation should be considered. One is the relapse setting, particularly in patients with aggressive disease at presentation and who have an early relapse (o2 years) after an optimal induction followed by ASCT. In this situation, the probability of a mid or long-term disease control with the currently available antimyeloma agents is very unlikely. Even more controversial is the use of allogeneic transplant as part of the front-line therapy. However, Moreau et al. 11 have recently recognized a subset of patients with high-risk cytogenetics, defined by the presence of t(4;14) or del 17p, in addition to either high LDH or ISS 3 who have a dismal prognosis with a median OS of 19 months and a 3-year OS of 24%. This subgroup of patients is considered as an ultrahigh-risk myeloma subset who, despite an initial response, become soon refractory to all the effective therapies currently available. These patients deserve novel treatment approaches and are potentially candidates to receive an allogeneic procedure as part of their first-line therapy. Although the general perception is that patients with MM tolerate allografting more poorly than patients with other hematologic malignancies, an EBMT analysis show that when adjusted for risk factors, outcomes for patients with MM are not different. 26 Concerning the prophylaxis of aGVHD, alternative strategies to the classical regimen with a calcineurine inhibitor plus MTX or mycophenylate mofetil are ongoing in a number of clinical trials. 27 In this setting, the administration of high-dose CY early posttransplant depletes alloreactive T cells from the donor and host and can inhibit both, graft rejection and GVHD. 28 This strategy has been used in the field of haploidentical transplantation, a modality of allogeneic transplant associated with a high rate of GVHD, with promising results. 27, 29 Alternative strategies to reduce the incidence of post-transplant relapse, such are the use of toxicityreduced conditioning regimens 30 or the use of post-transplant maintenance therapies with novel agents are also promising.
In conclusion, although allo-MAC in patients with MM is associated with a high nonrelapse mortality, about 10% of the patients can be cured with this procedure. Unfortunately, the RIC regimen is also associated with a high incidence of severe aGVHD resulting in a high TRM. However, about 30% of patients undergoing an allo-RIC can achieve long-term disease control, with a significant cure fraction. Thus, allogeneic transplantation can be of benefit in patients with early relapse as well as in the first-line setting for patients with ultrahigh-risk myeloma. Finally, rather than abandon a procedure with a curative potential, innovative approaches basically aimed at decreasing the incidence of aGVHD should be investigated until other less aggressive treatment strategies result in a real long-term benefit for this population of patients with very high-risk myeloma.
